Quince Therapeutics, Inc. (QNCX)

NASDAQ: QNCX · IEX Real-Time Price · USD
2.22
-0.09 (-3.70%)
Aug 16, 2022 3:33 PM EDT - Market open
-3.70%
Market Cap 81.36M
Revenue (ttm) n/a
Net Income (ttm) -83.31M
Shares Out 36.73M
EPS (ttm) -2.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 152,783
Open 2.26
Previous Close 2.30
Day's Range 2.22 - 2.37
52-Week Range 1.78 - 110.64
Beta 1.22
Analysts Sell
Price Target n/a
Earnings Date Aug 8, 2022

About QNCX

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August ... [Read more...]

Industry Biotechnology
IPO Date May 9, 2019
Employees 55
Stock Exchange NASDAQ
Ticker Symbol QNCX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

No stock price forecast available yet.

Price Target
n/a
Analyst Consensus: Sell
Stock Forecasts

News

Quince Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare ...

Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare ...